Campbell & Co Investment Adviser’s Enanta Pharmaceuticals ENTA Stock Holding History

Campbell & Co Investment Adviser’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.03M	Buy	70,764 +30,550	+76%	+$411K	0.05%	536
2026 Q1	$508K	Sell	40,214 -13,935	-26%	-$187K	0.03%	747
2025 Q4	$854K	Buy	54,149 +35,294	+187%	+$448K	0.04%	622
2025 Q3	$226K	Buy	+18,855	New	+$151K	0.02%	987
2022 Q4	–	Sell	-13,006	Closed	-$675K	–	824
2022 Q3	$675K	Buy	+13,006	New	+$760K	0.15%	220
2022 Q1	–	Sell	-3,600	Closed	-$269K	–	749
2021 Q4	$269K	Buy	+3,600	New	+$283K	0.09%	406
2017 Q4	–	Sell	-4,709	Closed	-$220K	–	429
2017 Q3	$220K	Buy	+4,709	New	+$189K	0.18%	261

Other funds holding ENTA

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KAM

Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SSC

Spruce Street Capital New York $510M AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Campbell & Co Investment Adviser's ENTA Position: Q2 2026 in Review

Campbell & Co Investment Adviser increased its Enanta Pharmaceuticals (ENTA) stake by 76% in Q2 2026, buying an estimated $411K and bringing the position to 70,764 shares worth $1.03M. The position accounts for 0.05% of the portfolio, ranked #536.

Campbell & Co Investment Adviser first reported a position in ENTA in Q3 2017 and has held it in 7 quarters since. 122 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

Campbell & Co Investment Adviser held 70,764 shares of Enanta Pharmaceuticals worth $1.03M as of Q2 2026.
Campbell & Co Investment Adviser bought 30,550 Enanta Pharmaceuticals shares in Q2 2026, an estimated $411K.
Enanta Pharmaceuticals made up 0.05% of Campbell & Co Investment Adviser's portfolio in Q2 2026, its #536 holding.
Campbell & Co Investment Adviser first reported a position in Enanta Pharmaceuticals in Q3 2017 and has held it in 7 quarters since.
122 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.